Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
<h4>Background</h4>In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM.<h4>Patients and...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0064354 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849320838340280320 |
|---|---|
| author | Bo Yang Rui-li Yu Xiao-hua Chi Xue-chun Lu |
| author_facet | Bo Yang Rui-li Yu Xiao-hua Chi Xue-chun Lu |
| author_sort | Bo Yang |
| collection | DOAJ |
| description | <h4>Background</h4>In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM.<h4>Patients and methods</h4>Databases were searched using the terms "lenalidomide or revlimid AND multiple myeloma."RCTs evaluating initial or maintenance therapeutic outcomes were included. Main outcome measures were response rates, progression-free survival (PFS), overall survival, and adverse events.<h4>Results</h4>Seven trials were included (N = 192-614 participants). Lenalidomide doses and treatment regimens differed between trials. Complete response (CR) and very good partial response (VGPR) risk ratios (RR) favored lenalidomide over placebo (CR = 2.54, 95% confidence interval [CI] = 1.29-5.02; VGPR = 2.82, 95% CI = 1.30-6.09). The PFS hazard ratio favored lenalidomide over placebo (0.37, 95% CI = 0.33-0.41). For adverse events, neutropenia, deep vein thrombosis (DVT), infection, and hematologic cancer RR favored placebo over lenalidomide (neutropenia: 4.74, 95% CI = 2.96-7.57; DVT: 2.52; 95% CI: 1.60-3.98; infection: 1.98; 95% CI: 1.50-2.62; hematologic cancer: 3.20; 95% CI: 1.28-7.98).<h4>Conclusions</h4>Lenalidomide is an effective treatment for MM; however, treatment-related adverse events must be considered and appropriate adjustments and/or prophylactic treatment should be initiated where possible. |
| format | Article |
| id | doaj-art-df36b7601dfa412d9924d73b25364d55 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-df36b7601dfa412d9924d73b25364d552025-08-20T03:49:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0185e6435410.1371/journal.pone.0064354Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.Bo YangRui-li YuXiao-hua ChiXue-chun Lu<h4>Background</h4>In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM.<h4>Patients and methods</h4>Databases were searched using the terms "lenalidomide or revlimid AND multiple myeloma."RCTs evaluating initial or maintenance therapeutic outcomes were included. Main outcome measures were response rates, progression-free survival (PFS), overall survival, and adverse events.<h4>Results</h4>Seven trials were included (N = 192-614 participants). Lenalidomide doses and treatment regimens differed between trials. Complete response (CR) and very good partial response (VGPR) risk ratios (RR) favored lenalidomide over placebo (CR = 2.54, 95% confidence interval [CI] = 1.29-5.02; VGPR = 2.82, 95% CI = 1.30-6.09). The PFS hazard ratio favored lenalidomide over placebo (0.37, 95% CI = 0.33-0.41). For adverse events, neutropenia, deep vein thrombosis (DVT), infection, and hematologic cancer RR favored placebo over lenalidomide (neutropenia: 4.74, 95% CI = 2.96-7.57; DVT: 2.52; 95% CI: 1.60-3.98; infection: 1.98; 95% CI: 1.50-2.62; hematologic cancer: 3.20; 95% CI: 1.28-7.98).<h4>Conclusions</h4>Lenalidomide is an effective treatment for MM; however, treatment-related adverse events must be considered and appropriate adjustments and/or prophylactic treatment should be initiated where possible.https://doi.org/10.1371/journal.pone.0064354 |
| spellingShingle | Bo Yang Rui-li Yu Xiao-hua Chi Xue-chun Lu Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS ONE |
| title | Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. |
| title_full | Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. |
| title_fullStr | Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. |
| title_full_unstemmed | Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. |
| title_short | Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. |
| title_sort | lenalidomide treatment for multiple myeloma systematic review and meta analysis of randomized controlled trials |
| url | https://doi.org/10.1371/journal.pone.0064354 |
| work_keys_str_mv | AT boyang lenalidomidetreatmentformultiplemyelomasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ruiliyu lenalidomidetreatmentformultiplemyelomasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaohuachi lenalidomidetreatmentformultiplemyelomasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xuechunlu lenalidomidetreatmentformultiplemyelomasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |